Literature DB >> 24615849

Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide.

Takaaki Kodawara1, Satohiro Masuda, Yoshitaka Yano, Kazuo Matsubara, Toshiaki Nakamura, Mikio Masada.   

Abstract

The interaction between mycophenolate (MPA) and quinolone antibiotics such as ciprofloxacin is considered to reduce the enterohepatic recycling of MPA, which is biotransformed in the intestine from MPA glucuronide (MPAG) conjugate excreted via the biliary system; however, the molecular mechanism underlying this biotransformation of MPA is still unclear. In this study, an in vitro system was established to evaluate β-glucuronidase-mediated deconjugation and to examine the influence of ciprofloxacin on the enzymatic deconjugation of MPAG and MPA resynthesis. Resynthesis of MPA via deconjugation of MPAG increased in a time-dependent manner from 5 to 60 min in the presence of β-glucuronidase. Ciprofloxacin and phenolphthalein-β-d-glucuronide (PhePG), a typical β-glucuronidase substrate, significantly decreased the production of MPA from MPAG in the β-glucuronidase-mediated deconjugation system. In addition, enoxacin significantly inhibited the production of MPA from MPAG, while levofloxacin and ofloxacin had no inhibitory effect on MPA synthesis. Pharmacokinetic analysis revealed that ciprofloxacin showed a dose-dependent inhibitory effect on MPA production from MPAG via β-glucuronidase with a half-maximal inhibitory concentration (IC50 ) value of 30.4 µm. While PhePG inhibited the β-glucuronidase-mediated production of MPA from MPAG in a competitive manner, ciprofloxacin inhibited MPA synthesis via noncompetitive inhibition. These findings suggest that the reduction in the serum MPA concentration during the co-administration of ciprofloxacin is at least in part due to the decreased enterohepatic circulation of MPA because of noncompetitive inhibition of deconjugation of MPAG by intestinal β-glucuronidase.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MPAG; ciprofloxacin; drug interaction; β-glucuronidase

Mesh:

Substances:

Year:  2014        PMID: 24615849     DOI: 10.1002/bdd.1894

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  6 in total

1.  Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial-associated diarrhea in a kidney transplant recipient with Crohn's disease: A case report.

Authors:  Ryota Tanaka; Asami Matsumoto; Ryosuke Tatsuta; Tadasuke Ando; Toshitaka Shin; Hiromitsu Mimata; Hiroki Itoh
Journal:  Clin Case Rep       Date:  2022-06-05

2.  Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity.

Authors:  Ze-Yu Zhong; Bin-Bin Sun; Nan Shu; Qiu-Shi Xie; Xian-Ge Tang; Zhao-Li Ling; Fan Wang; Kai-Jing Zhao; Ping Xu; Mian Zhang; Ying Li; Yang Chen; Li Liu; Lun-Zhu Xia; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

Review 3.  Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.

Authors:  Paul Awolade; Nosipho Cele; Nagaraju Kerru; Lalitha Gummidi; Ebenezer Oluwakemi; Parvesh Singh
Journal:  Eur J Med Chem       Date:  2019-12-04       Impact factor: 6.514

4.  Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception.

Authors:  Samuel J Pellock; Benjamin C Creekmore; William G Walton; Naimee Mehta; Kristen A Biernat; Andrew P Cesmat; Yamuna Ariyarathna; Zachary D Dunn; Bo Li; Jian Jin; Lindsey I James; Matthew R Redinbo
Journal:  ACS Cent Sci       Date:  2018-07-12       Impact factor: 14.553

Review 5.  Pharmacokinetic Drug-Drug Interactions Between Immunosuppressant and Anti-Infective Agents: Antimetabolites and Corticosteroids.

Authors:  Edward T Van Matre; Gowri Satyanarayana; Robert L Page 2nd; Marilyn E Levi; JoAnn Lindenfeld; Scott W Mueller
Journal:  Ann Transplant       Date:  2018-01-23       Impact factor: 1.530

6.  Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity.

Authors:  Michael R Taylor; Kyle L Flannigan; Hannah Rahim; Amina Mohamud; Ian A Lewis; Simon A Hirota; Steven C Greenway
Journal:  Sci Adv       Date:  2019-08-07       Impact factor: 14.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.